L40.0 K50.0
Conditions
Interventions
Group 1:
40 patients in whom the diagnosis of psoriasis (psoriasis) made ??new or confirmed
Procedures and examinations: Submission of a stool sample, one blood sample, a thin colonoscopy (bowel capsule Photographie) and colonoscopy, removal of a skin tissue sample
Diagnosis: stool and blood samples are analyzed by ELISA, skin tissue sample is examined by analysis Topoproteom
Group 2: 10 asymptomatic volunteers and patients without symptoms or diseases of the g
Diagnosis: stool and blood samples are analyzed by ELISA, skin tissue sample is examined by analysis Topoproteom
Sponsors
Universitätsklikum Magdeburg
Klinik für Dermatologie und Venerologie
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 10 asymptomatic subjects in cancer prevention - 40 patients with psoriasis without gastrointestinal symptoms Aged between 18 and 75 years. - Written inform consent
Exclusion criteria
Exclusion criteria: Gastrointestinal malignant tumors at medical history and current - Diseases that make endoscopic examinations impossible - Patients with psoriasis vulgaris in the 4 weeks prior inclusion into the study treated with systemic methotrexate, cyclosporine, retinoids, Glucocorticoids or biologics
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determining the prevalence of increased fecal and systemic calprotectin levels in patients with psoriasis vulgaris | — |
Secondary
| Measure | Time frame |
|---|---|
| Endoscopic and histological evaluation of the ileum and colon of patients with psoriasis vulgaris by ileo-colonoscopy - capsule-endoscopic examination of the small intestine of patients with psoriasis vulgaris for the presence of Crohn's disease of the duodenum, jejunum or ileum - Correlation of the measured systemic cutaneous and fecal Calprotectin values with the disease activity of psoriasis vulgaris and with the endoscopic and histological activity levels of IBD - Topoproteom analysis of tissue samples from skin and intestine in patients with psoriasis vulgaris regarding Th17-mediated inflammatory processes - Evaluating the impact of a disease-specific therapy on the progression of psoriasis in patients with evidence of IBD | — |
Countries
Germany
Contacts
Public ContactMichael Bellutti
Universitätsklikum Magdeburg Klinik für Dermatologie und Venerologie
Outcome results
None listed